Syra Health Corp. Class A (SYRA) AI Stock Analysis

• Market Cap: $955.13K
• Dividend Yield: N/A
• Average Volume (3M): 9.76K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.40
• Revenue Growth: 14.07%
• EPS Growth: 76.85%
• Country: US
• Employees: 57
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): >-0.01
• Shares Outstanding: 11,339,169
• 10 Day Avg. Volume: 11,249
• 30 Day Avg. Volume: 9,759
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.94
• Enterprise Value/Revenue: -0.11
• Enterprise Value/Gross Profit: -0.36
• Enterprise Value/Ebitda: 0.64
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: $0.00 ▼(-100.00% Downside)

Syra Health Corp. faces significant challenges with profitability and cash flow, which are reflected in its financial performance score. The technical analysis indicates a bearish trend, and the valuation is unattractive due to negative earnings and lack of dividends. These factors combine to result in a low overall stock score.

Syra Health Corp. Class A Business Overview & Revenue Model

Company Description

Syra Health Corp. Class A (SYRA) is a healthcare-focused company that specializes in providing innovative solutions and services to improve patient care and streamline healthcare operations. Operating within the healthcare technology sector, Syra Health develops and integrates advanced digital health platforms, telemedicine services, and data analytics tools that empower healthcare providers and enhance patient engagement. The company's core offerings aim to increase accessibility, reduce costs, and improve health outcomes across various healthcare settings.

How the Company Makes Money

Syra Health Corp. generates revenue primarily through its subscription-based model for its digital health platforms, where healthcare providers pay a recurring fee for access to its technology and services. Additionally, the company earns income from transaction fees related to telemedicine consultations and data analytics services. Strategic partnerships with healthcare organizations and technology firms further enhance its revenue streams by enabling joint offerings and expanding market reach. The company's focus on improving operational efficiency for healthcare providers translates into cost savings, making its solutions attractive, which in turn drives customer acquisition and retention.

Syra Health Corp. Class A Financial Statement Overview

Summary

Syra Health shows strong revenue growth but faces significant profitability and cash flow challenges. The balance sheet indicates low leverage, but historical negative equity poses risks. Operational efficiencies and cash generation need improvement for sustainable financial health.

Income Statement

The company has shown a revenue growth rate of 44.7% from 2023 to 2024, indicating strong top-line growth. However, the net profit margin is negative at -47.1% in 2024, showing ongoing profitability challenges. The gross profit margin improved slightly to 20.7%, but the EBIT and EBITDA margins remain negative, reflecting operational inefficiencies.

Balance Sheet

The debt-to-equity ratio is relatively low at 0.16, indicating conservative leverage. However, the return on equity is negative due to net losses. The equity ratio is 78.3%, suggesting a strong capital structure. Despite these strengths, the negative equity in previous years highlights potential financial instability.

Cash Flow

The free cash flow is negative and deteriorated by 6.1% from 2023 to 2024, indicating cash flow challenges. The operating cash flow to net income ratio is not favorable as both are negative, indicating inefficiencies in converting earnings into cash flows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.06M	7.98M	5.52M	5.62M	1.41M	0.00
Gross Profit	2.47M	1.65M	1.41M	1.06M	430.35K	0.00
EBITDA	-1.41M	-3.68M	-2.84M	-2.07M	-3.07K	-4.27K
Net Income	-1.46M	-3.76M	-2.94M	-2.12M	-3.28K	-4.27K
Balance Sheet
Total Assets	3.47M	3.68M	4.92M	2.32M	536.89K	3.00K
Cash, Cash Equivalents and Short-Term Investments	2.31M	2.40M	3.28M	3.34K	100.01K	3.00K
Total Debt	108.88K	452.08K	248.10K	934.84K	342.86K	3.00K
Total Liabilities	1.06M	800.76K	910.07K	1.61M	544.04K	7.17K
Stockholders Equity	2.41M	2.88M	4.01M	710.10K	-7.15K	-4.17K
Cash Flow
Free Cash Flow	-542.27K	-2.94M	-2.77M	-2.37M	-94.49K	0.00
Operating Cash Flow	-542.27K	-2.93M	-2.76M	-2.24M	-88.20K	0.00
Investing Cash Flow	0.00	-11.11K	-15.25K	-121.26K	-6.29K	0.00
Financing Cash Flow	1.25M	2.06M	6.05M	2.27M	191.50K	36.00K

Syra Health Corp. Class A Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYRA, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.08, and below the 200-day MA of 0.17, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.36 is Neutral, neither overbought nor oversold. The STOCH value of 31.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SYRA.

Syra Health Corp. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AMS	―	$13.67M	-5.68	-9.49%	―	26.61%	-156.30%
PIII	―	$63.54M	-0.18	-138.17%	―	4.20%	-54.16%
CCM	―	$23.88M	-1.05	―	―	-22.38%	56.66%
MODVQ	―	$14.35K	>-0.01	―	―	-0.70%	-2.38%
CCEL	―	$35.04M	-73.48	―	8.91%	-0.29%	94.56%
SYRA	―	$955.13K	-0.52	-64.70%	―	14.07%	76.85%

Syra Health Corp. Class A Corporate Events

Syra Health Corp. Appoints Radhika Mereddy to Board

On August 13, 2025, Syra Health Corp. appointed Radhika Mereddy to its Board of Directors. Ms. Mereddy’s compensation will align with that of other non-employee directors, and there are no special arrangements or related party transactions influencing her appointment, despite her being a principal stockholder in several companies.

Syra Health Reports Q2 Gains Amid Strategic Growth

Syra Health Corp., a healthcare technology company, focuses on enhancing health outcomes through innovative technology products and services, primarily in the mental health and population health sectors. In its latest earnings report, Syra Health announced steady revenue of $1.9 million for the second quarter of 2025, with significant growth in its Population Health unit, which saw a 197% increase compared to the previous year. The company also reported a substantial improvement in gross margin, which rose to 38.7%, and a notable reduction in its earnings per share loss to ($0.01) from ($0.21) in the prior year. Key financial highlights include a 95% reduction in net loss to $64,000 and a significant decrease in operating expenses by 53%, reflecting effective cost management. Additionally, Syra Health is expanding its footprint in the private sector with new contracts and has achieved ISO 27001:2022 certification, underscoring its commitment to data security. Looking ahead, Syra Health is cautiously optimistic, focusing on scaling successful strategies and maximizing shareholder value, despite potential challenges from government budget constraints that could impact revenue timing and volume.